Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2022

View Archived Issues

GTX-0196 shows complete tumor growth suppression in models of AML

Storm Therapeutics divulges new METTL3 inhibitors

New MRGPRX2 antagonists identified at GlaxoSmithKline

PRISM BioLab discovers Notch signaling inhibitors

Leukos Biotech patents serotonin 5-HT1B receptor antagonists

Ingenew BioPharma synthesizes new IL-1beta, IL-6 and TNF-alpha release inhibitors

In times of need, fat cells take on immune functions

Janssen describes discovery of improved Mcl-1 inhibitor JNJ-4355

MJFF grant supports Asceneuron's preclinical evaluation of ASN-51 for Parkinson's disease

Dianthus closes series A financing to support development of antibody complement therapeutics

CRD-1600 demonstrates robust immune modulatory properties in vitro and in vivo

Studies show KRAS G12C inhibitor APG-1842 is potent, bioavailable and highly selective

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...